More articles from MTA I: Radiopharmaceutical Therapy Posters

You have access
177Lu-EDTMP for bone pain palliation in patients with bone metastases: Pharmacokinetics and toxicity evaluation using dose escalation schedule
Shabana Saeed, John Zaknun, Ghazal Jameel, Naseer Ahmed, Javaid Irfan, Shazia Fatima, Ahmad Qureshy, Muhammad Shahzad Afzal and Giuliano Mariani

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1211;
You have access
177Lu-Bevacizumab a potential melanoma theragnostic agent
Ximena Camacho, Victoria Calzada, María Fernanda García, Marcelo Fernadez, Thomas Quinn, Susan Deutscher, Omar Alonso, Juan Pablo Gambini and Pablo Cabral

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1199;
You have access
Injection with 177Lu-octreotate reveals distinct gene expression response in kidney tissue
Emil Schüler, Toshima Parris, Nils Rudqvist, Khalil Helou and Eva Forssell-Aronsson

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1190;
You have access
Molecular radiotherapy with 131 iodine metaiodobenzylguanidine in carcinoid tumors - Are we making a difference?
R. Chakravartty, Gillian Vivian, B. Corcoran, S. Al-Shahwan, L. Devlin, Muriel Buxton-Thomas and N. Mulholland

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1192;
You have access
Y-90 PET/CT for localization of Yttrium-90 microspheres - Post radioembolization
Sankaran Shrikanthan, Vamsi Kunam and Shyam Srinivas

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1202;
You have access
Therapeutic response evaluation in patients with neuroendocrine tumors treated with 177Lu-DOTATATE
Santosh Gupta, Nishikant Damle and Chandrasekhar Bal

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1178;
You have access
Correlation of the pretherapeutic Ga-68-DOTATOC tumor SUV with the subsequently absorbed dose of Lu-177-DOTA-Octreotate
Samer Ezziddin, Jonas Lohmar, Charlotte Yong-Hing, Amir Sabet, Hojjat Ahmadzadehfar, Hans Jürgen Biersack, Stefan Guhlke and Karl Reichmann

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1184;
You have access
Effects and safety of repeated 131I metaiodobenzylguanidine (MIBG) radiotherapy in patients with malignant pheochromocytoma and paraganglioma
Keiichiro Yoshinaga, Shozo Okamoto, Tohru Shiga, Ataru Sazawa, Nobuo Shinohara, Katsuya Nonomura and Nagara Tamaki

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1193;
You have access
Combination Lu-177 BB2r antagonist/chemotherapy control of prostate cancer: A preclinical evaluation
Lindsay Donnelly, Tammy Rold, Kelsey Richmond, Ashley Szczodroski, Gary Sieckman, Shadi Haddadin and Timothy Hoffman

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1194;
You have access
Auger electron-emitting radiopharmaceuticals targeting telomerase
Mark Jackson, Philip Waghorn and Katherine Vallis

Journal of Nuclear Medicine May 1, 2012, 53 (supplement 1) 1213;

Main menu

User menu

Search

More articles from MTA I: Radiopharmaceutical Therapy Posters

Pages